A Phase 3 interventional study of adalimumab in Psoriasis, sponsored by Abbott. Completed at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 22nd largest by enrollment, is one of 2 that started in 2008, is one of 26 in phase 3, and was the 5th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
16 studies in Psoriasis by Abbott: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Psoriasis by Abbott, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2008, is one of 6 in phase 3, and was the 6th registered.
Abbott’s Psoriasis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 16 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.
This 16-week multicenter, open-label study was designed to evaluate the efficacy and safety of a loading dose of 80 mg adalimumab, followed by 40 mg adalimumab every other week in the treatment of psoriasis in patients with a sub-optimal response to etanercept, methotrexate (MTX), or Narrow band Ultraviolet - B (NB-UVB).
Approximately 150 participants were planned for 3 sub-studies: 80 participants with sub-optimal response to etanercept, 40 participants with sub-optimal response to MTX, and 30 participants with sub-optimal response to NB-UVB. Actual enrollment was 82 participants with sub-optimal response to etanercept, 41 participants with sub-optimal response to MTX, and 29 participants with sub-optimal response to NB-UVB.
Screening was performed at least 96 hours and no more than 31 days before the Baseline visit (Week 0). A participant who was eligible for the study based on sub-optimal response to one treatment (MTX, NB-UVB, or etanercept) was required to discontinue that treatment within a specified time before first dose of adalimumab (see descriptions of sub-study groups). In addition, if the participant was also receiving another qualifying treatment, he/she was required to have discontinued the other treatment at least 30 days before the Baseline visit (Week 0).
Adalimumab was administered by subcutaneous (SC) injection. At the Baseline Visit (Week 0), all participants received an initial dose of 80 mg adalimumab SC. Every other week (odd-numbered weeks) from Week 1 to Week 15, participants received 40 mg adalimumab SC.
This was a single group assignment study, that is, all participants received the same treatment; however, data were summarized for 3 groups (sub-studies) that were defined by psoriasis treatments participants received before entering this study: methotrexate, etanercept, or narrow-band, ultraviolet-B.
Efficacy was evaluated using the Physician's Global Assessment (PGA) of disease severity, and patient-reported outcomes: Patient's Global Assessment (PTGA) of disease severity, the Psoriasis-related Pruritus Assessment, the Dermatology Life Quality Index (DLQI), a visual analog scale (VAS) for plaque psoriasis and psoriatic arthritis pain, the Medical Outcomes Study (MOS) Sleep Scale, and the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI: SHP).
Serious and nonserious adverse events were summarized by sub-study of participants (suboptimal response to MTX, suboptimal response to NB-UVB, and suboptimal response to etanercept).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: adalimumab
Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
Also known as: ABT-D2E7, Humira
Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16
The PGA is a 6-point scale used to measure the severity of a patient's disease. Plaque elevation, scaling, and erythema are rated from 0= clear (no plaque elevation; no scaling; erythema=hyperpigmentation, pigmented macules, diffuse faint pink or red coloration) to 5=very severe (plaque elevation=very marked; scaling=very coarse; erythema=very severe \[extreme red coloration, dusky to deep red coloration\]).
Time frame: Week 16
Number of Participants Achieving a PGA of Clear (0) at Week 16
Time frame: Week 16
Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening
Time frame: From Screening to Week 16
Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8
The Patient's Global Assessment of Psoriasis-Severity is a rating of how well their disease is controlled. 0=complete disease control; 1=good disease control; 2=limited disease control; 3=uncontrolled disease.
Time frame: Weeks 2, 4, and 8
Dermatology Life Quality Index (DLQI) Total Score
The DLQI has 10 items and 6 subscales: symptoms and feelings (Q 1 and 2), daily activities (Q 3 and 4), leisure (Q 5 and 6), work and school (Q 7), personal relationships (Q 8 and 9), and treatment (Q 10). Participants rate how much their skin problem affected their life in previous week. Responses are 0 (not at all) to 3=very much. DLQI=total of scores for all items; max=30; min=0.
Time frame: From Screening to Week 4 and Week 16
Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16
DLQI total score of 0 indicates psoriasis had no effect at all on participant's life.
Time frame: Week 4 and Week 16
Psoriasis-related Pruritus Assessment
The Psoriasis-related Pruritus Assessment is a scale for evaluating pruritus-related to psoriasis over the previous week; values range from 0 (no itching) to 10 (severe itching). A decrease in score indicates an improvement in pruritus.
Time frame: From Screening to Week 16
Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis
The participant rates his/her pain during the previous week on a 100 mm VAS, from 0=no pain to 100=pain as bad as it could be. A decrease in score indicates improvement.
Time frame: From Screening to Week 16
Percent Work Time Missed Due to Psoriasis
Work and activity impairment due to psoriasis were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), a 6-item questionnaire that measures effect of psoriasis on number of hours worked and the number of hours missed from work. It also measures the effect on productivity and regular activities: 0=no effect on work/daily activities; 10=psoriasis prevented me from working/doing daily activities. Decreases in values on each part indicate improvement. At Screening, percent time missed in the previous week ranged from 0% to 40%.
Time frame: From Screening to Week 16
Percent Overall Work Impairment Due to Psoriasis
Percent overall work impairment was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) (described above). At Screening, overall impairment ranged from 0% to 94%. A decrease in percent overall work impairment indicates improvement.
Time frame: From Screening to Week 16
Percent Impairment While Working Due to Psoriasis
Percent impairment while working was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, impairment while working ranged from 0% to 90%. A decrease in percent impairment indicates improvement.
Time frame: From Screening to Week 16
Percent Activity Impairment Due to Psoriasis
Percent impairment in regular activities was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, activity impairment due to psoriasis ranged from 0% to 90%.
Time frame: From Screening to Week 16
Sleep Problems Index II
Sleep Problems Index of the Sleep Scale from the Medical Outcomes Study reflects sleep disturbance, perceived sleep adequacy, daytime somnolence, and awakening short of breath or with headache. Participant rates each item from "none of the time" to "all of the time" for the previous 4 weeks. Scores are transformed to 0 to 100 scale; lower scores indicate less impairment. Decrease in score indicates improvement.
Time frame: From Screening to Week 16
Patients who were previously treated with etanercept, methotrexate (MTX), or narrow-band ultraviolet-B (NB-UVB) and had a sub-optimal response were recruited for participation in the study.
| Milestone | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Started | 41 | 29 | 82 |
| Completed | 39 | 24 | 73 |
| Not completed | 2 | 5 | 9 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 2 | 4 |
| Withdrew: Did not meet exclusion criteria | 0 | 0 | 2 |
| Withdrew: Serious adverse event | 0 | 1 | 0 |
| Withdrew: Noncompliant with drug administration | 0 | 0 | 1 |
The PGA is a 6-point scale used to measure the severity of a patient's disease. Plaque elevation, scaling, and erythema are rated from 0= clear (no plaque elevation; no scaling; erythema=hyperpigmentation, pigmented macules, diffuse faint pink or red coloration) to 5=very severe (plaque elevation=very marked; scaling=very coarse; erythema=very severe \[extreme red coloration, dusky to deep red coloration\]).
| Participants | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16 | 25 | 14 | 40 |
| Participants | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Number of Participants Achieving a PGA of Clear (0) at Week 16 | 15 | 6 | 10 |
| Participants | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening | 32 | 23 | 59 |
The Patient's Global Assessment of Psoriasis-Severity is a rating of how well their disease is controlled. 0=complete disease control; 1=good disease control; 2=limited disease control; 3=uncontrolled disease.
| Participants | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Week 2 | 5 | 0 | 9 |
| Week 4 | 13 | 7 | 20 |
| Week 8 | 22 | 13 | 29 |
The DLQI has 10 items and 6 subscales: symptoms and feelings (Q 1 and 2), daily activities (Q 3 and 4), leisure (Q 5 and 6), work and school (Q 7), personal relationships (Q 8 and 9), and treatment (Q 10). Participants rate how much their skin problem affected their life in previous week. Responses are 0 (not at all) to 3=very much. DLQI=total of scores for all items; max=30; min=0.
| Change in scores on a scale | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Week 4 | -4.8 ± 5.89 | -5.2 ± 5.45 | -3.3 ± 4.93 |
| Week 16 | -7.0 ± 7.45 | -6.5 ± 6.44 | -3.8 ± 5.66 |
DLQI total score of 0 indicates psoriasis had no effect at all on participant's life.
| Participants | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Week 4 | 6 | 2 | 2 |
| Week 16 | 12 | 6 | 17 |
The Psoriasis-related Pruritus Assessment is a scale for evaluating pruritus-related to psoriasis over the previous week; values range from 0 (no itching) to 10 (severe itching). A decrease in score indicates an improvement in pruritus.
| Change in scores on a scale | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Psoriasis-related Pruritus Assessment | -2.9 ± 3.90 | -3.0 ± 2.96 | -1.7 ± 3.24 |
The participant rates his/her pain during the previous week on a 100 mm VAS, from 0=no pain to 100=pain as bad as it could be. A decrease in score indicates improvement.
| Change in scores on a scale | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis | -14.7 ± 24.41 | -21.4 ± 30.01 | -12.7 ± 29.90 |
Work and activity impairment due to psoriasis were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), a 6-item questionnaire that measures effect of psoriasis on number of hours worked and the number of hours missed from work. It also measures the effect on productivity and regular activities: 0=no effect on work/daily activities; 10=psoriasis prevented me from working/doing daily activities. Decreases in values on each part indicate improvement. At Screening, percent time missed in the previous week ranged from 0% to 40%.
| Change in percent time missed | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Percent Work Time Missed Due to Psoriasis | 0.7 ± 3.43 | 1.3 ± 4.75 | -0.1 ± 1.85 |
Percent overall work impairment was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) (described above). At Screening, overall impairment ranged from 0% to 94%. A decrease in percent overall work impairment indicates improvement.
| Change in % overall work impairment | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Percent Overall Work Impairment Due to Psoriasis | -4.0 ± 28.06 | -6.4 ± 19.75 | -2.8 ± 16.92 |
Percent impairment while working was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, impairment while working ranged from 0% to 90%. A decrease in percent impairment indicates improvement.
| Change in % impairment while working | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Percent Impairment While Working Due to Psoriasis | -5.5 ± 30.31 | -8.0 ± 19.35 | -1.5 ± 18.46 |
Percent impairment in regular activities was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, activity impairment due to psoriasis ranged from 0% to 90%.
| Change in percent activity impairment | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Percent Activity Impairment Due to Psoriasis | -13.3 ± 33.08 | -12.2 ± 25.62 | -4.7 ± 23.03 |
Sleep Problems Index of the Sleep Scale from the Medical Outcomes Study reflects sleep disturbance, perceived sleep adequacy, daytime somnolence, and awakening short of breath or with headache. Participant rates each item from "none of the time" to "all of the time" for the previous 4 weeks. Scores are transformed to 0 to 100 scale; lower scores indicate less impairment. Decrease in score indicates improvement.
| Change in scores on a scale | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Sleep Problems Index II | -9.7 ± 18.01 | -7.7 ± 15.82 | -2.0 ± 14.57 |
Collected over 26 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sub-optimal Response to MTX | — | 0/41 (0%) | 19/41 (46.3%) |
| Sub-optimal Response to Narrow-band Ultraviolet-B | — | 1/29 (3.4%) | 12/29 (41.4%) |
| Sub-optimal Response to Etanercept | — | 4/82 (4.9%) | 20/82 (24.4%) |
| Event | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| CellulitisInfections and infestations | 0/41 | 1/29 | 0/82 |
| Coronary artery diseaseCardiac disorders | 0/41 | 0/29 | 1/82 |
| Diverticulitis Meckel'sCongenital, familial and genetic disorders | 0/41 | 0/29 | 1/82 |
| Diverticular perforationGastrointestinal disorders | 0/41 | 0/29 | 1/82 |
| Food poisoningGastrointestinal disorders | 0/41 | 0/29 | 1/82 |
| PeritonitisGastrointestinal disorders | 0/41 | 0/29 | 1/82 |
| Helicobacter pylori identification test positiveInvestigations | 0/41 | 0/29 | 1/82 |
| ObesityMetabolism and nutrition disorders | 0/41 | 0/29 | 1/82 |
| Event | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/41 | 1/29 | 5/82 |
| Injection site erythemaGeneral disorders | 3/41 | 1/29 | 1/82 |
| NasopharyngitisInfections and infestations | 3/41 | 0/29 | 3/82 |
| FatigueGeneral disorders | 2/41 | 2/29 | 2/82 |
| PharyngitisInfections and infestations | 0/41 | 2/29 | 0/82 |
| GlaucomaEye disorders | 2/41 | 0/29 | 0/82 |
| Injection site reactionGeneral disorders | 2/41 | 0/29 | 0/82 |
| BronchitisInfections and infestations | 2/41 | 0/29 | 0/82 |
| ContusionInjury, poisoning and procedural complications | 2/41 | 0/29 | 1/82 |
| SunburnInjury, poisoning and procedural complications | 2/41 | 0/29 | 0/82 |
| Age Continuous(years) | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept | Total |
|---|---|---|---|---|
| Mean | 47.4 ± 13.11 | 45.7 ± 14.60 | 48.3 ± 13.70 | 47.6 ± 13.67 |
| Sex: Female, Male(Participants) | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept | Total |
|---|---|---|---|---|
| Female | 13 | 13 | 35 | 61 |
| Male | 28 | 16 | 47 | 91 |
| Region of Enrollment(participants) | Sub-optimal Response to MTX | Sub-optimal Response to Narrow-band Ultraviolet-B | Sub-optimal Response to Etanercept | Total |
|---|---|---|---|---|
| United States | 26 | 10 | 70 | 106 |
| Canada | 15 | 19 | 12 | 46 |
The record gives a start of Jan 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab